Hepagene Therapeutics

Executive Summary

Hepagene Therapeutics is a clinical-stage biotechnology company based in Shanghai, China, focused on developing novel oral therapies for chronic hepatitis B (CHB) and related liver diseases. The company's lead candidate is a potentially first-in-class oral agent targeting the hepatitis B virus lifecycle, aiming to achieve functional cures for CHB—a significant unmet medical need affecting over 250 million people globally, with a high prevalence in China. Hepagene's pipeline is in Phase 2, and the company is privately held with no disclosed funding or valuation. The company's strategy leverages a deep understanding of HBV biology to develop small molecules that could offer improved efficacy and convenience over current standard-of-care injections, potentially positioning it as a key player in the quest for a functional cure. Given the large patient population and the urgent need for more effective treatments, Hepagene's progress is closely watched by investors and industry partners.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead HBV candidate55% success
• TBDPotential licensing or partnership deal for China or global rights40% success
• Q1 2026Regulatory update for Phase 2b/3 trial design70% success